Erin Sult (Brand)

Leveraging 20+ years of extensive expertise in cell-based assay development, immunology, and molecular biology methodologies to advance Oncology research and therapeutic innovation. Skilled in CRISPR Cas9 and lenti-viral transfection/transduction, and isolation and purification of primary and tumor cell types, with a proven track record of driving projects through fast-paced, cross-functional environments. Proficient in data analysis tools and assay optimization to support critical decision-making.

• Checkpoint inhibitor combinations in a human mixed leukocyte reaction., Erin Sult, Carl Hay, Qihui Huang, Stacy Fuhrmann, Robert Hollingsworth, Kris F. Sachsenmeier, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 04/18/15, Philadelphia, PA
• MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment., Carl Hay, Erin Sult, Qihui Huang, Scott Hammond, Kathy Mulgrew, Kelly McGlinchey, Stacy Fuhrmann, Raymond Rothstein, Edmund Poon, Ross Stewart, Robert Hollingsworth, Kris Sachsenmeier, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 04/18/15, Philadelphia, PA
• Levels and enzyme activity of CD73 in primary samples from cancer patients., Qihui Huang, Nicholas M. Durham, Erin Sult, Yuling Wu, Jenny Liu, Nicholas Holoweckyj, Laurie Iciek, Robert Hollingsworth, Brett Hall, Ronald Herbst, Ching Ching Leow, Kris Sachsenmeier, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 04/18/15, Philadelphia, PA
• Screening for Combinations of Molecules Affecting Immune Regulatory Pathways in a Human Mixed Leukocyte Reaction., Erin Sult, Cellomics Users Group Meeting, 05/13/14, Baltimore, MD
• Calculating the statistical significance of synergy in cancer drug combinations., Erin Sult, Wei Zhao, Harry Yang, Robert Hollingsworth, Kris F. Sachsenmeier, Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, 04/06/13, Washington, DC
• The avidity hypothesis: comparing bispecific and monospecific antibodies in preclinical oncology models., Kris F. Sachsenmeier, Nazzareno Dimasi, Qihui Huang, Erin Sult, Binyam Bezabeh, Ryan Fleming, Carl Hay, Helen Zhong, Shannon Breen, Changshou Gao, Balaji Agoram, Lutz Jermutus, Robert Hollingsworth, Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, 04/06/13, Washington, DC
• New Target Discovery for Oncology Utilizing Phenotypic Selection and Primary NSCLC Patient Tumors., Nick Holoweckyj, Alan Sandercock, Sandrine Guillard, Steven Rust, Carl Hay, Erin Brand, John Meekin, Qihui Huang, Kris Sachsenmeier, Ralph Minter, Robert Hollingsworth, Emma Bowden, Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 03/31/12, Chicago, IL
• The Application of Phage Display for the Identification of Novel Target Antigens in Cancer., Steven Rust, Sandrine Guillard, Alan Sandercock, Vignesh Venkatraman, Kris Sachsenmeier, Carl Hay, Erin Brand, Emma Bowden, Nick Holoweckyi, Nick, Ralph Minter, Lutz Jermetus, The 28th International Conference 'Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells', 06/20/11, Mykonos, Greece

• Radiate Award, 2021, In recognition of pushing hard and accelerating the progress of AZD2936 from CDID to IND in record time.
• SLAS Journal Achievement Award, 2017
• Discovery Reader's Choice Award, 2017, A New Bliss Independence Model to Analyze Drug Combination Data
• Director's Award
• 07/01/10
• 10/01/09

• Dimasi, N., Fleming, R., Sachsenmeier, K., Bezabeh, B., Hay, C., Wu, J., Sult, E., Rajan, S., Zhuang, L., Cariuk, P., Buchanan, A., Bowen, M., Wu, H., Gao, C., Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain., MAbs, 3, 438-454, 2017
• Vijayan, D., Barkauskas, D., Stannard, K., Sult, E., Buonpane, R., Takeda, K, Teng, M, Sachsenmeier, K., Hay, C, Smyth, M., Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases., OncoImmunology, 6, 5, e1312044, 2017
• Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S., McGlinchey, K., Hammond, S., Rothstein, R., Rios-Doria, J., Poon, E., Holoweckyj, N., Durham, N., Leow, C., Diedrich, G., Damshroder, M., Herbst, R., Hollingsworth, R., Sachsenmeier, K., Targeting CD73 in the tumor microenvironment with MEDI9447., OncoImmunology, 5, 8, e1208875, 2016
• Young, A., Ngiow, SF., Barkauskas, DS., Sult, E., Hay, C., Blake, SJ., Huang, Q., Liu J., Takeda, K., Teng, MWL., Sachsenmeier, K., Smyth, MJ., Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-Tumor Immune Responses., Cancer Cell, 30, 3, 391-403, 2016
• Birse, C. E., Lagier, R., FitzHugh, W., Pass, H., Rom, W., Edell, E., Bungum, A., Maldonado, F., Jett, J., Mesri, M., Sult, E., Joseloff, E., Li, A., Heidbrink, J., Dariwal, G., Danis, C., Tomic, J., Bruce, R., Moore, P., He, T., Lewis, M., Ruben, S., Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium., Clinical Proteomics, 12, 1, 18, 2015
• Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R., Yang, H., A New Bliss Independence Model to Analyze Drug Combination Data., Journal of Biomolecular Screening, 19, 5, 817-821, 2014
• Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, D., Karlsson, R., Brand, E., Lowne, D., Elvin, J., Flynn, M., Kurosawa, G., Hollingsworth, R., Jermutus, R., Minter, R., Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative' breast cancer cell type., Molecular Cancer, 12, 1, 11, 2013
• Mesri, M., Birse, C., Heidbrink, J., McKinnon, K., Brand, E., Bermngham, C., Field, B., FitzHugh, W., He, T., Ruben, S., Moore, P., Identification and Characterization of Angiogenesis Targets through Proteomic Profiling of Endothelial Cells in Human Cancer Tissues., PLoS ONE, 8, 11, e78885, 2013
• Sachsenmeier, K. F., Hay, C., Brand, E., Clarke, L., Rosenthal, K, Guillard, S., Rust, S., Minter, R., Hollingsworth, R., Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening., J Biomol Screen, 72, 2012
• Nicol, G. R., Han, M., Kim, J., Birse, C., Brand, E., Nguyen, A., Mesri, M., Fitzhugh, W., Kaminker, P., Moore, P., Ruben, S., He, T., Use of an Immunoaffinity-Mass Spectrometry-based Approach for the Quantification of Protein Biomarkers from Serum Samples of Lung Cancer Patients., Molecular & Cellular Proteomics, 7, 10, 1974-1982, 2008

• THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND A2A RECEPTOR INHIBITOR AND USES THEREOF, Sachsenmeier, K, Sult, E., Hay, C, Poon, E., 11/10/15, 09/20/17, Europe, EP3218407A1
• BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF, Hay, C., Sachsenmeier, K., Sult, E., Huang, Q., Pavlik, P., Damschroder, M., Cheng, L., Diedrich, G., Rios-doria, J., Hammond, S., Minter, R., Rust, S., Guillard, S., Hollingsworth, R., Jermutus, L., Durham, N., Leow, C., Antonysamy, M., Geoghegan, J., Lu, X., Rosenthal, K., 11/09/15, 07/07/16, United States, World, Europe, US20160194407, WO/2016/075099A1, EP3218406
• THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF, Sachsenmeier, K, Sult, E., Hay, C, Poon, E., 11/10/15, 05/12/16, United States, World, US20160129108, WO/2016/075176A1